Evidence map›Paper›PMID 37667764›Full record

ArticleIJU case reports2023

A case of sequential medical therapy for advanced ureteral cancer in Li-Fraumeni syndrome.

Minami Une, Ryo Fujiwara, Arisa Ueki, Ryosuke Oki, Tetsuya Urasaki, Kentaro Inamura, Shunji Takahashi, Junji Yonese, Takeshi Yuasa

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Minami UneDepartment of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0003-3004-4605
Ryo FujiwaraDepartment of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0001-6566-1430
Arisa UekiDepartment of Clinical Genetic Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Ryosuke OkiDepartment of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Tetsuya UrasakiDepartment of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Kentaro InamuraDepartment of Pathology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Shunji TakahashiDepartment of Medical Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Junji YoneseDepartment of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Takeshi YuasaDepartment of Genitourinary Oncology, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0002-8924-6730
Japanese Foundation For Cancer Research · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Li-Fraumeni syndrome, an autosomal dominant cancer predisposition syndrome caused by a pathogenic variant of Case presentation: A 73 years-old female patient, who had been diagnosed genetically as Li-Fraumeni syndrome; suffered from chondrosarcoma in the left pelvic joint, bilateral breast cancer, endometrial cancer, gastric cancer, and colon cancer in her history. She was diagnosed as unresectable advanced urothelial cancer during continuous magnetic resonance imaging surveillance, underwent avelumab maintenance therapy after the combination of gemcitabine and cisplatin chemotherapy. The efficacies of gemcitabine and cisplatin chemotherapy and avelumab maintenance therapy were good. Conclusion: We report an advanced urothelial cancer in a patient with Li-Fraumeni syndrome who demonstrated good efficacies to sequential medical therapy.

Indexed as

advanced urothelial canceravelumabimmune checkpoint inhibitorLi–Fraumeni syndromeTP53 pathogenic variant

Identifiers

PMID37667764
PMCPMC10475342
OpenAlexW4384340873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.